Why Eli Lilly Stock Was a Winner Today

A hopeful report about a potential blockbuster drug currently in development and news of an expansion of manufacturing capability helped push Eli Lilly (NYSE: LLY) stock skyward on Tuesday. Shares of the massive U.S. pharmaceutical company closed the day more than 2% higher in value, on a session when the S&P 500 index landed slightly in the red. Reuters published an article speculating that orforglipron, Eli Lilly's next-generation obesity drug currently in development, could earn Food and Drug Administration (FDA) approval by the end of this year. Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool